Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
UT-15C SR added to background oral therapy for pulmonary arterial hypertension
ACTRN12606000169549Phase 3Not yet recruiting
- Sponsor
- United Therapeutics Corporation
- Start
- Jul 2006
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in pulmonary arterial hypertension (PAH) comparing UT-15C SR with Placebo (2 arms). Primary endpoint: Change in 6-minute walk distance. Planned start Jul 2006; status: not yet recruiting.
02
Drugs
TransCon treprostinil
03
Conditions
pulmonary arterial hypertension (PAH)
Beyond the preview
Go deeper on ACTRN12606000169549.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12606000169549.